Product name: Ampicillin sodium and Oxacillin sodium for injection
Shelf Life: 3 Years
Bacterial infections caused by a microflora that is sensitive to the drug: sinusitis, tonsillitis, otitis, bronchitis, cystitis, cholecystitis, urethritis, gonorrhea, skin and soft tissue infections, erysipelas, infected dermatoses, dysentery, etc.
Prevention of postoperative complications; infection in newborns.
Severely leaking infections (sepsis, endocarditis, pneumonia, meningitis, postpartum infection).
Dosing and Administration
Ampioks injected intramuscularly or intravenously (struino or drip).
A single dose of the drug for adults and children over 14 years is 0.5-1 g, daily dose - 2-4 g.
Children under 1 year are prescribed in a daily dose of 100-200 mg / kg body weight, from 1 year to 7 years - no 100 mg / kg body weight per day, from 7 to 14 years - 50 mg / kg body weight per day. The daily dose is administered in 3-4 divided doses at intervals of 6-8 hours.
Duration of treatment from 5-7 days to 3 weeks.
For intramuscular injection, the contents of the vial (0.5 g) are dissolved in 5 ml of sterile water for injection.
For intravenous fluid administration, a single dose of the drug is dissolved in 10-15 ml of water for injection or isotonic sodium chloride solution and injected slowly for 2-3 minutes.
For intravenous drip administration, adults are given a single dose of the drug in a 100-200 ml isotonic sodium chloride solution or 5-10% glucose solution and injected at a rate of 60-80 drops per minute.
When drip introduction, children are used as a solvent 5-10% glucose solution (30-100 ml, depending on age).
The solutions are used immediately after preparation. It is inadmissible to add other drugs to them.
Nausea, vomiting, diarrhea; allergic reactions (foot rash, edema of the vulva, rhinitis, conjunctivitis); rarely anaphylactic shock.
Hypersensitivity to the drug, infectious mononucleosis. lymphocytic leukemia.
Interaction with other drugs.
Bactericidal antibiotics (aminoglycosides, cephalelorrhoea, vancomycin, rifampicin)
have a synergistic effect, bacterinostatic agents (macrolides, chloramphenicol
lnncozamides, tetracyclines, sulfonamides) antagonistic action.
Dhurstiki increase the concentration of the drug in the blood plasma and increase the risk of developing toxic effects.
Allouurinol increases the risk of skin rash.
Data on drug overdose are absent.
The use of the drug during pregnancy is possible only in cases where the expected benefit of therapy for the mother significantly exceeds the negative potential risk for the fetus. At the time of treatment, breastfeeding should be discontinued.
When using high doses in patients with renal insufficiency, a toxic effect on the central nervous system is possible.
0.5 g of powder for the preparation of solution for injections in vials, hermetically sealed with rubber stopper, aluminum cap and plastic lid.
Store in a dry place at room temperature.